Amgen reports positive results from OSLER-1 and OSLER-2 trials of Repatha
Repatha is a new investigational low-density lipoprotein cholesterol (LDL-C)-lowering medication. A total of 4,465 patients were enrolled in the trial who had completed one of 12 Phase II
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.